[Postnatal corticosteroids in preterm infants with immature lung disease]

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Pharmacology

Background:

• Corticosteroid use in preterm infants with immature lungs is debated due to potential adverse effects versus benefits in reducing respiratory support.
• Immature lung disease in preterm infants often necessitates supplemental oxygen and mechanical ventilation.
• Evaluating the risk-benefit profile of corticosteroids is crucial for optimizing neonatal respiratory care.

Purpose of the Study:

• To assess the impact of intravenous and inhaled corticosteroids on the need for supplemental oxygen and mechanical ventilation in preterm infants.
• To investigate potential adverse effects associated with corticosteroid treatment in this population.
• To provide evidence for the judicious use of corticosteroids in managing severe immature lung disease in neonates.

Main Methods:

• Retrospective cohort study of preterm infants (2000-2014) treated with intravenous (n=28) or inhaled (n=30) corticosteroids for immature lung disease.
• Control group matched for gestational age, with one control infant for each corticosteroid-treated infant.
• Data collected on respiratory support, weight gain, and adverse outcomes like cerebral palsy.

Main Results:

• Both intravenous and inhaled corticosteroids significantly decreased the need for supplemental oxygen.
• Intravenous corticosteroids led to a significant reduction in the need for mechanical ventilation.
• Infants receiving intravenous corticosteroids showed less weight gain during treatment but no significant long-term differences; no significant increase in adverse effects like cerebral palsy was observed.

Conclusions:

• Intravenous and inhaled corticosteroids effectively reduce supplemental oxygen requirements in preterm infants with immature lung disease.
• Intravenous corticosteroids facilitate earlier weaning from mechanical ventilation.
• Corticosteroid therapy appears justifiable in selected preterm infants with severe immature lung disease, given the observed benefits and lack of significant adverse effects.